Cord blood ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
60 | 再生不良性貧血 | 21 |
60. 再生不良性貧血
臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166
Showing 1 to 10 of 21 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2100047288 | 2021-06-01 | 2021-06-11 | Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in myelodysplastic syndromes/aplastic anemia patients: a clinical observation study Efficacy and safety of combined immunosuppressive therapy plus umbilical cord bloodinfusion in myelo ... | Efficacy and safety of combined immunosuppressive therapy plus umbilical cord blood infusion in myelodysplastic syndromes/aplastic anemia patients: a clinical observation study Efficacy and safety of combined immunosuppressive therapy plus umbilical cord bloodinfusion in myelo ... | myelodysplastic syndromes/aplastic anemi | Experimental group1:According to the classification, ATG + CsA/CSA alone is used as the pretreatment plan/supportive treatment + non-blood cord blood stem cell infusion treatment;Experimental group2:Decitabine+cytarabine/decitabine alone is used as the pretreatment plan/supportive treatment+non-blood cord blood stem cell infusion treatment according to the classification; Experimental group1:According to the classification, ATG + CsA/CSA alone is used as the pretreatment ... | The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital) | NULL | Recruiting | 18 | 90 | Both | Experimental group1:10;Experimental group2:10; | China | |
2 | ChiCTR1900026462 | 2019-08-19 | 2019-10-11 | Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cells co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia Clinical study for umbilical cord bloodmesenchymal stem cells combined with peripheral blood stem ce ... | Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cell co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia--single-center, single-arm, open clinical study Clinical study for umbilical cord bloodmesenchymal stem cells combined with peripheral blood stem ce ... | aplastic anemia,AA | Cass series:low dose post Cyclophosphamide and Mesenchymal stem cell; | Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital | NULL | Recruiting | Both | Cass series:20; | China | |||
3 | NCT03173937 (ClinicalTrials.gov) | June 13, 2017 | 31/5/2017 | Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome Unrelated Umbilical Cord BloodTransplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using ... | Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome Unrelated Umbilical Cord BloodTransplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using ... | Severe Aplastic Anemia;Hypo-Plastic MDS;Myelodysplastic Syndrome (MDS) | Biological: Omidubicel (former CordIn) | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Recruiting | 4 Years | 75 Years | All | 37 | Phase 1/Phase 2 | United States |
4 | NCT02838992 (ClinicalTrials.gov) | February 2017 | 6/7/2016 | ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia ATG Combined With Cyclophosphamide And Cord BloodTransfusion in Treating Patients With Severe Aplast ... | Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord BloodTransfusion in Tr ... | Aplastic Anemia | Drug: Rabbit ATG, (Genzyme);Drug: Cy;Drug: CsA;Biological: Cord blood | Jinan Military General Hospital | Shandong University of Traditional Chinese Medicine;Jining Medical University;Affiliated Hospital of Weifang Medical University;Guangzhou First People's Hospital;Harbin Hematology and Oncology Institute;JINING No.1 People's Hospital;JIANGXI Provincal People's Hospital;Jinhua Central Hospital;Linyi People's Hospital;Shandong Cord Blood Bank;Qingdao Center Medical Group;Qingdao University;Taian City Central Hospital;Yantai Yuhuangding Hospital;Yishui Central Hospital of LINYI;Institute of Hematology & Blood Diseases Hospital;Shengjing Hospital Shandong University of Traditional Chinese Medicine;Jining Medical University;Affiliated Hospital of ... | Not yet recruiting | 1 Year | 60 Years | All | 130 | Phase 4 | China |
5 | NCT02745717 (ClinicalTrials.gov) | January 2016 | 7/4/2016 | The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia The Efficacy of Immunosuppressive Therapy Combined With Cord BloodTransfusion in Treatment of Severe ... | The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia The Efficacy of Immunosuppressive Therapy Combined With Cord BloodTransfusion in Treatment of Severe ... | Severe Aplastic Anemia | Drug: Thymoglobulin;Procedure: Cord blood;Drug: Cyclosporine Oral Product | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Ruijin Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai Tongji Hospital, Tongji University School of Medicine;Zhejiang Provincial Hospital of TCM Ruijin Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai Tongji Ho ... | Completed | N/A | 60 Years | All | 60 | Phase 4 | China |
6 | NCT01861093 (ClinicalTrials.gov) | October 16, 2015 | 21/5/2013 | Safety Study of Cord Blood Units for Stem Cell Transplants | A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord BloodUnits (CBUs) Manuf ... | Aplastic Anemia;Leukemia;Myelodysplastic Syndrome (MDS);Lymphoma | Biological: Cord Blood Units | National Heart, Lung, and Blood Institute (NHLBI) | National Cancer Institute (NCI);National Institute of Allergy and Infectious Diseases (NIAID);National Cord Blood Program, New York Blood Center National Cancer Institute (NCI);National Institute of Allergy and Infectious Diseases (NIAID);Nation ... | Recruiting | 4 Years | N/A | All | 500 | Phase 2 | United States |
7 | NCT01586455 (ClinicalTrials.gov) | April 2013 | 25/4/2012 | Human Placental-Derived Stem Cell Transplantation | A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells C ... | Mucopolysaccharidosis I;Mucopolysaccharidosis VI;Adrenoleukodystrophy;Niemann-Pick Disease;Metachromatic Leukodystrophy;Wolman Disease;Krabbe's Disease;Gaucher's Disease;Fucosidosis;Batten Disease;Severe Aplastic Anemia;Diamond-Blackfan Anemia;Amegakaryocytic Thrombocytopenia;Myelodysplastic Syndrome;Acute Myelogenous Leukemia;Acute Lymphocytic Leukemia Mucopolysaccharidosis I;Mucopolysaccharidosis VI;Adrenoleukodystrophy;Niemann-Pick Disease;Metachrom ... | Drug: Human Placental Derived Stem Cell | New York Medical College | NULL | Completed | 0 Years | 55 Years | All | 43 | Phase 1 | United States |
8 | NCT01553461 (ClinicalTrials.gov) | February 21, 2012 | 13/3/2012 | Transplants With Unlicensed Preserved Cord Blood | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord BloodUnits (CBUs) f ... | Myelodysplastic Syndrome (MDS);Hematologic Neoplasms;Hematologic Diseases;Severe Aplastic Anemia | Biological: Cord Blood Transplant | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Recruiting | 4 Years | 99 Years | All | 500 | Phase 1/Phase 2 | United States |
9 | NCT01500161 (ClinicalTrials.gov) | November 2011 | 18/11/2011 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Pooled Unrelated Donor Umbilical Cord BloodTransplant For Hematologic Malignancy Needing Allogeneic ... | A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood (UCB) Transplant For Patients With Hematologic Malignancies Needing Allogeneic Stem Cell Transplant But Do Not Have A Related HLA-Matched Donor A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood(UCB) Transplant For Patients With He ... | Acute Myelogenous Leukemia;Acute Lymphocytic Leukemia;Chronic Lymphocytic Leukemia;Chronic Myelogenous Leukemia;Hodgkins Disease;Non-Hodgkins Lymphoma;Aplastic Anemia;Multiple Myeloma;Myelodysplastic Syndrome Acute Myelogenous Leukemia;Acute Lymphocytic Leukemia;Chronic Lymphocytic Leukemia;Chronic Myelogeno ... | Drug: Busulfan;Drug: Clofarabine;Drug: Fludarabine;Drug: Melphalan;Drug: Carmustine;Drug: Etoposide;Drug: Cytarabine Drug: Busulfan;Drug: Clofarabine;Drug: Fludarabine;Drug: Melphalan;Drug: Carmustine;Drug: Etoposide; ... | Texas Oncology Cancer Center | NULL | Terminated | 18 Years | 65 Years | Both | 1 | Phase 2 | United States |
10 | NCT01351545 (ClinicalTrials.gov) | October 2011 | 9/5/2011 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord BloodUnits (CBUs) f ... | Hematologic Malignancies;Inherited Disorders of Metabolism;Inherited Abnormalities of Platelets;Histiocytic Disorders;Acute Myelogenous Leukemia (AML or ANLL);Acute Lymphoblastic Leukemia (ALL);Other Acute Leukemia;Chronic Myelogenous Leukemia (CML);Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;Other Leukemia;Hodgkin Lymphoma;Non-hodgkin Lymphoma;Multiple Myeloma/ Plasma Cell Disorder (PCD);Inherited Abnormalities of Erythrocyte Differentiation or Function;Disorders of the Immune System;Autoimmune Diseases;Severe Aplastic Anemia Hematologic Malignancies;Inherited Disorders of Metabolism;Inherited Abnormalities of Platelets;Hist ... | Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord bloodunits (C ... | Center for International Blood and Marrow Transplant Research | National Marrow Donor Program | Recruiting | N/A | N/A | All | 99999 | United States |